While increased folate metabolism in cancer cells is a well-reported phenomenon, and the use of antifolates was one of the earliest forms of leukemia chemotherapy (57), the role of SLC19A1 is largely unstudied in the context of tumor escape and invasion. Here, SLC19A1 is linked to cancer.